Charles Zhu

ORCID: 0000-0003-1431-1806
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nanoparticle-Based Drug Delivery
  • Radiopharmaceutical Chemistry and Applications
  • Nanoplatforms for cancer theranostics
  • Telomeres, Telomerase, and Senescence
  • RNA Interference and Gene Delivery
  • Prostate Cancer Treatment and Research
  • Science, Research, and Medicine
  • Mass Spectrometry Techniques and Applications
  • Radiation Therapy and Dosimetry
  • Electric Vehicles and Infrastructure
  • Click Chemistry and Applications
  • Advanced Battery Technologies Research
  • Monoclonal and Polyclonal Antibodies Research
  • Epigenetics and DNA Methylation
  • Colorectal Cancer Treatments and Studies
  • Hydrogels: synthesis, properties, applications
  • Renal Diseases and Glomerulopathies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • RNA and protein synthesis mechanisms
  • Dialysis and Renal Disease Management
  • Peptidase Inhibition and Analysis
  • Glycosylation and Glycoproteins Research
  • Chronic Kidney Disease and Diabetes
  • Cancer, Hypoxia, and Metabolism
  • PARP inhibition in cancer therapy

Texas Tech University
2022-2023

Texas Tech University Health Sciences Center
2022-2023

Delta Air Lines (United States)
2015-2020

Rutgers, The State University of New Jersey
2012-2017

Research Triangle Park Foundation
2015

Cornell University
2011

St George Hospital
2008

UNSW Sydney
2008

National Cancer Institute
2006

Center for Cancer Research
2006

This study evaluates targeted liposomes loaded with the α-particle generator <sup>225</sup>Ac to selectively kill prostate-specific membrane antigen (PSMA)–expressing cells aim assess their potential for antivascular radiotherapy. <b>Methods:</b> In this study, PEGylated were and labeled mouse antihuman PSMA J591 antibody or A10 aptamer. The targeting selectivity, extent of internalization, killing efficacy evaluated on monolayers prostate cancer intrinsically expressing (human LNCaP rat...

10.2967/jnumed.113.125476 article EN Journal of Nuclear Medicine 2013-12-12

ABSTRACT The regulation by two transcriptional activators of flagellar expression (FlhD and FlhC) the chemotaxis methyl-accepting protein Aer was studied with glass slide DNA microarrays. An flhD ::Kan insertion an aer deletion were independently introduced into Escherichia coli K-12 strains, effects upon gene investigated. Altogether, altered 29 operons known function. Among them Aer, which in turn regulated a subset these operons, namely, ones involved anaerobic respiration...

10.1128/jb.185.2.534-543.2003 article EN Journal of Bacteriology 2003-01-02

A subset of cancers across multiple histologies with predominantly poor outcomes use the alternative lengthening telomeres (ALT) mechanism to maintain telomere length, which can be identified robust biomarkers. ALT has been reported prevalent in high-risk neuroblastoma and certain sarcomas, are a major clinical challenge that lack targeted therapeutic approaches. Here, we found variety pediatric adult cancer histologies, including carcinomas. Patient-derived cell lines from neuroblastomas,...

10.1158/0008-5472.can-22-0125 article EN Cancer Research 2022-08-10

We investigated the feasibility and efficacy of a drug delivery strategy to vascularized cancer that combines targeting selectivity with high uptake by targeted cells bioexposure delivered chemotherapeutics. Targeted lipid vesicles composed pH responsive membranes were designed reversibly form phase-separated domains, which are utilized tune vesicle's apparent functionality permeability. During circulation, mask functional ligands stably retain their contents. Upon extravasation in tumor...

10.1021/mp3002717 article EN Molecular Pharmaceutics 2012-11-07

// Takahiro Yoshida 1, *, $ , Kideok Jin * Hong Song 2 Sunju Park 1 David L. Huso 3, @ Zhe Zhang Han Liangfeng Charles Zhu 4 Frank Bruchertseifer 5 Alfred Morgenstern George Sgouros Saraswati Sukumar Department of Oncology, Johns Hopkins University School Medicine, Maryland, USA Radiology and Radiological Science, 3 Molecular Comparative Pathobiology, Biomedical Engineering, Rutgers University, Piscataway, NJ, European Commission, Joint Research Centre, Institute for Transuranium Elements,...

10.18632/oncotarget.8949 article EN Oncotarget 2016-04-23

Abstract This study aims to evaluate the effect on killing efficacy of intracellular trafficking patterns α-particle emitters by using different radionuclide carriers in setting targeted antivascular α-radiotherapy. Nanocarriers (lipid vesicles) prostate-specific membrane antigen (PSMA), which is unique human neovasculature for a variety solid tumors, were loaded with generator actinium-225 and compared PSMA-targeted radiolabeled antibody. Actinium-225 emits total four α-particles per decay,...

10.1158/1535-7163.mct-15-0207 article EN Molecular Cancer Therapeutics 2015-12-31

Abstract Malignant gliomas are aggressive forms of primary brain tumors characterized by a poor prognosis. The most successful treatment so far is the local implantation polymer carriers (Gliadel® wafers) for sustained release carmustine. To improve effectiveness drug treatment, new and pharmacological agents currently being investigated. Of particular interest set novel thermo‐gelling polymers controlled hydrophobic drugs such as paclitaxel (e.g., OncoGel™). Herein, we use computational...

10.1002/btpr.665 article EN Biotechnology Progress 2011-06-17

Effective targeting by uniformly functionalized nanoparticles is limited to cancer cells expressing at least two copies of targeted receptors per nanoparticle footprint (approximately ≥2 × 10(5) receptor cell); such a density supports the required multivalent interaction between neighboring and ligands from single nanoparticle. To enable selective below this density, on surface lipid vesicles were displayed in clusters that designed form acidic pH tumor interstitium. Vesicles with clustered...

10.1021/acs.langmuir.6b01464 article EN Langmuir 2016-07-29

&lt;div&gt;Abstract&lt;p&gt;A subset of cancers across multiple histologies with predominantly poor outcomes use the alternative lengthening telomeres (ALT) mechanism to maintain telomere length, which can be identified robust biomarkers. ALT has been reported prevalent in high-risk neuroblastoma and certain sarcomas, are a major clinical challenge that lack targeted therapeutic approaches. Here, we found variety pediatric adult cancer histologies, including carcinomas. Patient-derived cell...

10.1158/0008-5472.c.6514106.v1 preprint EN 2023-03-31
Coming Soon ...